Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program

Saturday, December 1, 2007 General News J E 4
SAN DIEGO, Nov. 30 Amylin Pharmaceuticals, Inc.(Nasdaq: AMLN) will be presenting at the Nasdaq 20th Investor Program inLondon on Thursday, December 6, 2007 at 7:15 a.m. PT / 3:15 p.m. GMT localtime in the UK. Berthold Lensker, Ph.D., Executive Director of EuropeanOperations, will be providing a corporate overview of Amylin Pharmaceuticals.

The live presentation will be webcast, and a recording will be madeavailable following the event. The webcast and recording will be accessiblethrough Amylin's corporate website, located at Toaccess the live webcast, please log on to Amylin's site approximately fifteenminutes prior to the presentation to register and download any necessary audiosoftware.

More information about the Nasdaq 20th Investor Program is available at:

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed toimproving lives through the discovery, development and commercialization ofinnovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection andBYETTA(R) (exenatide) injection. Amylin's research and development activitiesleverage the company's expertise in metabolism to develop potential therapiesto treat diabetes and obesity. Amylin is located in San Diego, Californiawith over 1,800 employees nationwide. Further information on AmylinPharmaceuticals is available at

SOURCE Amylin Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
World AIDS Day 2007
Vical Presentation at Military Pandemic Influenza ...